Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
December 6, 2024 |
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations.
How are payers responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act? Explore our findings.
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, we employed our RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations. This included national and regional Managed Care Organizations (MCOs), Pharmacy Directors (PDs), Integrated Delivery Networks (IDNs), and Pharmacy Benefit Managers (PBMs), representing a total of 96 million MCO/IDN lives and 115 million PBM lives.
Our findings reveal critical insights into how payers are adapting to the recent release of MFPs for key pharmaceutical products under the IRA. For example:
💡 Payers view the MFPs for the diabetes and cardiovascular products most favorably and plan to leverage them in upcoming commercial rebate negotiations. However, payers see unmet needs for further discounts for the immunology and oncology products.
💡 Payers are divided on preferring MFP over non-MFP products due to the potential for non-MFP products to offer more aggressive rebates or better clinical benefits.
View the graphic above for further details.
This is just the first glimpse into a larger narrative. Follow us on LinkedIn to view Part Two of our findings and stay tuned for our interim report within the coming weeks. This report will offer further detail as to how MFPs could reshape both payer strategies and the healthcare market.
You can find out more about our RPR stakeholder engagement platform and global network of 3500+ vetted stakeholders online or contact solutions@genesisrg.com if you have questions or would like to request a copy of the report in advance.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice…
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice…